Logo image
Back
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC
Journal article   Open access   Peer reviewed

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

David E. Gerber, Paul Swanson, Ariel Lopez-Chavez, Lucas Wong, Afshin Dowlati, Nathan A. Pennell, Damien M. Cronier, Amy Qin, Robert Ilaria, Jan Cosaert, …
Lung cancer (Amsterdam, Netherlands), v 111, pp 108-115
01 Sep 2017
DOI: https://doi.org/10.1016/j.lungcan.2017.07.009
PMID: 28838379
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://www.ncbi.nlm.nih.gov/pmc/articles/5672830View
Open

Abstract

NSCLC Olaratumab Paclitaxel/carboplatin PDGFR
•Olaratumab (IMC-3G3) is a fully human anti-PDGFR monoclonal antibody.•Olaratumab plus carboplatin-paclitaxel does not prolong PFS or OS in NSCLC.•PDGFR expression is rare in NSCLC tumor cells but common in NSCLC stroma.•The addition of olaratumab to chemotherapy is well tolerated. In non-small cell lung cancer (NSCLC), platelet-derived growth factor receptor (PDGFR) mediates angiogenesis, tissue invasion, and tumor interstitial pressure. Olaratumab (IMC-3G3) is a fully human anti-PDGFRα monoclonal antibody. This Phase II study assessed safety and efficacy of olaratumab+paclitaxel/carboplatin (P/C) versus P/C alone for previously untreated advanced NSCLC. Patients received up to six 21-day cycles of P 200mg/m2 and C AUC 6 (day 1)±olaratumab 15mg/kg (days 1 and 8). Primary endpoint was PFS. Olaratumab was continued in the olaratumab+P/C arm until disease progression. 131 patients were: 67 with olaratumab+P/C and 64 with P/C; 74% had nonsquamous NSCLC. Median PFS was similar between olaratumab+P/C and P/C (4.4 months each) (HR 1.29; 95% CI [0.86–1.93]; p=0.21). Median OS was similar between olaratumab+P/C (11.8 months) and P/C (11.5 months) (HR 1.04; 95% CI [0.68–1.57]; p=0.87). Both arms had similar toxicity profiles. All evaluable cases were PDGFR-negative by immunohistochemistry. Tumor stroma PDGFR expression was evaluable in 23/131 patients, of which 78% were positive. The addition of olaratumab to P/C did not result in significant prolongation of PFS or OS in advanced NSCLC. Olaratumab studies in other patient populations, including soft tissue sarcoma (NCT02783599), pancreatic cancer (NCT03086369), and pediatric malignancies (NCT02677116) are underway.

Metrics

12 Record Views
11 citations in Web of Science
9 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Oncology
Respiratory System
Logo image